The Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF) demonstrated the superiority of the sacubitril/valsartan (formerly known as LCZ696) over the angiotensin-converting enzyme inhibitor (ACEI) enalapril in patients with heart failure and reduced ejection fraction (HF-REF) [1]. This evidence concerns the gene ACE and heart failure.